Risk Factors Update Summary
- Addition of axatilimab to limited clinical testing may impact clinical benefit demonstration for patients.
- Increase in shares sold from 7 to 12 million in a public offering.
- Positive topline data announced for R/R KMT2Ar acute leukemia, NDA submitted under FDA's RTOR program.
- Addition of "bank failures" to risks. This change might lead to financial instability.
- Increased net loss reported from $149 million to $209 million for the year ended December 31, 2023.
- Change from "continues" to "exacerbated" regarding Russia-Ukraine war impact.
- Accumulated deficit rose from $693 million to $902 million as of December 31, 2023.
- Net proceeds rose from approximately $19 million to $42 million from common shares sale.
- Potential risks from public health crises and global geopolitical tensions highlighted, including ongoing wars.
- Changes in patent law could impact the value of intellectual property rights for product candidates.
- Increased frequency and severity of supply chain attacks may pose risks to operations.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1395937&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.